## **Announcement Summary**

# **Entity name**

**BCAL DIAGNOSTICS LIMITED** 

### **Announcement Type**

New announcement

### Date of this announcement

29/8/2023

# The Proposed issue is:

☑ An offer of securities under a securities purchase plan

☑ A placement or other type of issue

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
BDX	ORDINARY FULLY PAID	63,000,000

#### +Record date

25/8/2023

# Offer closing date

13/9/2023

#### +Issue date

18/9/2023

# Total number of +securities proposed to be issued for a placement or other type of issue

))	ASX +security code	+Security description	Maximum Number of +securities to be issued
	New class-code to be confirmed	Unlisted option	700,000
	BDX	ORDINARY FULLY PAID	24,000,000

# Proposed +issue date

1/9/2023

Refer to next page for full details of the announcement



# Part 1 - Entity and announcement details

#### 1.1 Name of +Entity

**BCAL DIAGNOSTICS LIMITED** 

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

# 1.2 Registered Number Type

**Registration Number** 

ABN

51142051223

1.3 ASX issuer code

**BDX** 

1.4 The announcement is

New announcement

#### 1.5 Date of this announcement

29/8/2023

# 1.6 The Proposed issue is:

☑ An offer of +securities under a +securities purchase plan

A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis? 
☑ No



Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

BDX: ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

**BDX: ORDINARY FULLY PAID** 

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

63,000,000

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? 

⊗ No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)? 
☑ No

Is the minimum acceptance unit based or dollar based? 

⊗ Dollar based (\$)

Please enter the minimum acceptance value

\$ 2.000

Is the maximum acceptance unit based or dollar based? 

⊗ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

# Froposed issue of securities

\$2,000, \$4,000, \$6000, \$8,000, \$10,000, \$15,000, \$20,000, \$25,000, \$30,000

#### Offer price details

Has the offer price been determined? 
⊗ No

In what currency will the offer be made?

AUD - Australian Dollar

### How and when will the offer price be determined?

The issue price will be \$0.10 or at least 80% of the Volume Weighted Average Price in the five days before issue (18 September 2023)

Describe all the applicable parcels available for this offer in number of securities or dollar value

## Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed? 
⊗ Yes

### Describe the scale back arrangements

BCAL may in its absolute discretion determine to apply a scale back to the extent and in the manner that it sees fit. In the event that demand exceeds 30% of BCAL's issued capital, applications will be scaled back. It is BCAL's current intention that scale backs due to excess demand be made pro rata, based on the number of shares held by applicants as at the Record Date (with fractional entitlements being rounded down to the nearest whole number of New Shares.

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

28/8/2023

4C.2 +Record date

25/8/2023

4C.3 Date on which offer documents will be made available to investors

30/8/2023

4C.4 Offer open date

30/8/2023

4C.5 Offer closing date

13/9/2023

4C.7 +lssı	ue date and las	st day for	entity to	announce	results of	+security
purchase	plan offer					

18/9/2023

Part	4D - Listing Rule requirements
	4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?   ✓ Yes
Part	4E - Fees and expenses
	4E.1 Will there be a lead manager or broker to the proposed offer?   ☑ No
	<b>4E.2</b> Is the proposed offer to be underwritten?   ☑ No
	4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?  ☑ No
	4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer
Part	4F - Further Information  4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
	1. Clinical studies
	Building out BCAL's clinical services laboratory
	General working capital.

© No

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

Any country outside of Australia and New Zealand

4F.3 URL on the entity's website where investors can download information about the proposed offer

www.bcaldiagnostics.com/news

4F.4 Any other information the entity wishes to provide about the proposed offer



### Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? 

☑ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

**BDX: ORDINARY FULLY PAID** 

Number of +securities proposed to be issued

24,000,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

What is the issue price per +security?

AUD - Australian Dollar

AUD 0.10000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? 

✓ Yes



Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? ☑ No

of the 'new' class of +securities on ASX? ☑ No

ASX +security code

+Security description

New class-code to be confirmed

Unlisted option

+Security type

**Options** 

Number of +securities proposed to be issued

700,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

✓ No

Please describe the consideration being provided for the +securities

To brokers for capital raising services

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

42,000.000000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

$\sim$	4	•		-1 -	etai	1 -
( )	nt	ınr	٦C	$\alpha$	וכזנ	10

+Security currency

**Exercise price** 

**Expiry date** 

AUD - Australian Dollar

AUD 0.2000

28/8/2026

Details of the type of +security that will be issued if the option is exercised

**BDX: ORDINARY FULLY PAID** 

Number of securities that will be issued if the option is exercised

700000

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Options to be issued to brokers on the basis of 1 option for every \$1.50 raised.

Part 7C - Timetable

7C.1 Proposed +issue date

1/9/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? 
☑ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 

✓ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

24000000

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⊗ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? 

✓ Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 
⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? 

⊗ No

### Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue? 

⊗ Yes

7E.1a Who is the lead manager/broker?

PacPartners and MST Financial Services

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

4% selling fee (excluding Chair List), \$80,000 management fee each and 1 option for every \$1.50 of aggregate capital raised.

**7E.2** Is the proposed issue to be underwritten? 

⊗ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

## 7F.01 The purpose(s) for which the entity is issuing the securities

- 1. Clinical studies
- 2. Building out BCAL's clinical services laboratory
- 3. General working capital.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? 
⊗ No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)